A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies

The vast majority of patients with plasma cell neoplasms die of progressive disease despite high response rates to novel agents. Malignant plasma cells are very radiosensitive, but the potential role of radioimmunotherapy (RIT) in the management of plasmacytomas and multiple myeloma (MM) has undergo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Green, Damian J., Orgun, Nural N., Jones, Jon C., Hylarides, Mark D., Pagel, John M., Hamlin, Donald K., Wilbur, D.S., Lin, Yukang, Fisher, Darrell R., Kenoyer, Aimee L., Frayo, Shani L., Gopal, Ajay K., Orozco, Johnnie J., Gooley, Theodore A., Wood, Brent L., Bensinger, William I., Press, Oliver W.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3970848/
https://ncbi.nlm.nih.gov/pubmed/24371230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1589
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items